
-
No talks over Spurs future for Postecoglou after Europa glory
-
Osaka 'enjoying' battle to get back to top
-
Man Utd need to change 'a lot of things': Amorim
-
Sexually assaulted and smeared in excrement: Uganda activist details torture in Tanzania
-
Bangladesh govt calls for unity to stop 'return of authoritarianism'
-
Quartararo takes third successive MotoGP pole
-
England end Williams's resistance as Zimbabwe fight hard in one-off Test
-
Germany mass stabbing suspect has 'psychological illness': police
-
Leclerc fastest in Monaco practice as Hamilton crashes
-
Gaza civil defence says 15 killed in Israeli strikes
-
Rashford, Diaz 'fantastic players': Barca coach Flick
-
Salah voted Premier League player of the season
-
Cannes hit by power cut as film festival draws to a close
-
Russia strikes Kyiv as hundreds more POWs exchanged with Ukraine
-
India name Shubman Gill as new Test captain before England series
-
'Seventh heaven': Tears and laughter as Ukrainian POWs return
-
German woman due in court after mass stabbing in Hamburg
-
Shubman Gill: Young 'Prince' leading India's post-Rohit, Kohli era
-
Suriname poised for cash inflow from newly discovered oil
-
India name Shubman Gill as new Test captain
-
Russia strikes Kyiv after first stage of major prisoner swap
-
Growing Arctic military presence worries Finland's reindeer herders
-
Venue dispute overshadows CAF Confederation Cup title decider
-
Thousands remain isolated as floods ease in eastern Australia
-
Rare wild cattle herded in Cambodia by helicopter
-
Doubt cast on claim of 'hints' of life on faraway planet
-
Japanese filmmaker Fukada casts queasy gaze on J-pop idols
-
Tennis's 'Big Three' reign unlikely to be repeated: Moya
-
At Roland Garros, the 'other' clay specialists have their work cut out
-
Forest chase Champions League dream as Liverpool party
-
Highlights from Cannes as film festival wraps up
-
Cannes closes with Iranian, Ukrainian films tipped for glory
-
Bae grabs lead but Wang makes charge in Mexican heat
-
UN chief says Gaza war in 'cruelest phase' as aid trucks looted
-
Winger Reece relishes Super Rugby try-scoring record
-
Griffin and Schmid share lead at Colonial
-
Venezuela opposition leader arrested ahead of tense election
-
US, Boeing reach deal to resolve MAX criminal case
-
Anthropic's Claude AI gets smarter -- and mischievious
-
Trump greenlights Nippon Steel 'partnership' with US Steel
-
German woman arrested after 17 stabbed at Hamburg station
-
Napoli back on top in Italy after sealing fourth Serie A crown
-
'Intense' Bath stay on track for treble with Challenge Cup glory
-
US Steel shares skyrocket after Trump greenlights Nippon 'partnership'
-
Napoli's key men in Serie A title triumph
-
Bath stay on track for treble with Challenge Cup glory
-
Conte's Napoli future uncertain even after Serie A title glory
-
McTominay steps out of United's shadow to become Napoli hero
-
Napoli claim fourth Serie A title as Inter fall short
-
UN expert says Guatemalan anti-corruption fighters persecuted

US health experts vote against MDMA as treatment for PTSD
A panel of US health experts convened by the Food and Drug Administration on Tuesday overwhelmingly voted against the use of MDMA, commonly known as ecstasy, to treat post-traumatic stress disorder.
PTSD, a debilitating mental health condition that develops after a person experiences or is threatened by traumatic events such as death, combat or sexual assault, affects an estimated five percent of Americans in any given year.
But pharmaceutical treatment options are so far limited to two antidepressants that require three months of dosing to take effect, and response rates to the medications have been found to be uneven.
California-based Lykos Therapeutics has based its request for regulatory approval on two clinical studies, each of which enrolled around 100 people, to evaluate MDMA used together with other psychological interventions such as talk therapy, against a placebo with talk therapy.
These two studies, published in the prestigious journal Nature Medicine, indicated MDMA was indeed both safe and highly effective at treating PTSD.
But nine out of 11 experts on the panel said available data was not enough to show the treatment was effective, and 10 out of 11 said the benefits did not outweigh the risks.
"I think this is a really exciting treatment. I'm really encouraged by the results to date," said one of the experts, Paul Holtzheimer of the National Center for PTSD.
"But I feel that both from an efficacy and a safety standpoint, it is still premature."
The vote by the panel of experts is non-binding, but the FDA rarely goes against their recommendations.
- Not enough side effect data -
MDMA -- methylenedioxymethamphetamine -- is a Schedule 1 drug under the Controlled Substances Act, and approving it for medical use would have represented a major shift.
In a briefing document put together ahead of the meeting, FDA staff raised concerns that although the studies were nominally "double-blinded" -- meaning neither those being tested nor their health care workers knew who received the treatment versus the placebo -- most people were able to accurately guess what they received.
This "functional unblinding," they argued, introduces bias and uncertainty into study outcomes.
FDA staff also criticized Lykos for not gathering sufficient side effect data, including whether participants experienced "euphoria" or "elated mood," which, they argued, "would be informative for an assessment of abuse potential or characterization of anticipated effects of the drug."
Reports from recreational use suggest MDMA has harmful impacts on heart and liver health -- but the company did not gather enough data in these areas, the FDA said.
- Research misconduct allegations -
Then there were troubling allegations of research impropriety linked to the trials that surfaced in a draft report by the nonprofit Institute for Clinical and Economic Review.
These include claims that the trials "pulled heavily from the existing community of those interested and involved in the use of psychedelics for possible psychological benefits."
Some patients told the nonprofit they were allegedly prevented from entering the long term-follow up study "and felt this was done to keep these negative outcomes out of the data set."
"We certainly take those allegations very seriously and are quite concerned by them," the FDA's Tiffany Farchione said during the meeting, adding a probe was ongoing.
Lykos has said a final decision from the FDA on authorization should come by mid-August.
If the agency were to authorize the treatment over the advisory panel's objections, there could be certain strict stipulations attached -- for example, that the drug only be dispensed in health care settings, with subjects carefully monitored and enrolled in a registry to document side effects.
A.Malone--AMWN